- Home
- M vs PTGX Comparison
M vs PTGX Comparison
Compare M & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- M
- PTGX
- Stock Information
- Founded
- M 1830
- PTGX 2006
- Country
- M United States
- PTGX United States
- Employees
- M N/A
- PTGX N/A
- Industry
- M Department/Specialty Retail Stores
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- M Consumer Discretionary
- PTGX Health Care
- Exchange
- M Nasdaq
- PTGX Nasdaq
- Market Cap
- M 4.8B
- PTGX 4.0B
- IPO Year
- M N/A
- PTGX 2016
- Fundamental
- Price
- M $19.46
- PTGX $76.60
- Analyst Decision
- M Hold
- PTGX Strong Buy
- Analyst Count
- M 10
- PTGX 9
- Target Price
- M $15.72
- PTGX $78.11
- AVG Volume (30 Days)
- M 6.9M
- PTGX 1.6M
- Earning Date
- M 11-25-2025
- PTGX 10-31-2025
- Dividend Yield
- M 3.76%
- PTGX N/A
- EPS Growth
- M 304.55
- PTGX N/A
- EPS
- M 1.77
- PTGX 0.80
- Revenue
- M $22,701,000,000.00
- PTGX $209,180,000.00
- Revenue This Year
- M N/A
- PTGX N/A
- Revenue Next Year
- M N/A
- PTGX $140.23
- P/E Ratio
- M $10.99
- PTGX $95.09
- Revenue Growth
- M N/A
- PTGX N/A
- 52 Week Low
- M $9.76
- PTGX $33.31
- 52 Week High
- M $19.99
- PTGX $93.25
- Technical
- Relative Strength Index (RSI)
- M 64.78
- PTGX 57.23
- Support Level
- M $19.24
- PTGX $73.08
- Resistance Level
- M $19.99
- PTGX $80.43
- Average True Range (ATR)
- M 0.51
- PTGX 2.54
- MACD
- M 0.06
- PTGX -0.45
- Stochastic Oscillator
- M 79.21
- PTGX 49.93
About M Macy's Inc
Founded in 1858 and based in New York City, Macy's operates about 450 stores under the Macy's name, nearly 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's names, and more than 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constitute about 62% of Macy's sales.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.